BUFORD,Theragenics has begun clinical trials of its novel approach for preventing restenosis, or the narrowing of leg arteries, following treatment for vascular disease using balloon angioplasty.

The company said 30 patients in as many as three treatment centers will take part in the TheraP trial. The procedure involves the insertion of a catheter that permits the depositing of a therapeutic dose of radiation in diseased areas as opposed to invasive surgery.

Theragenics: www.theragenics.com